Evidence map›Paper›PMID 36325402›Full record

ArticleRussian journal of bioorganic chemistry2022

Prospects for the Use of Marine Sulfated Fucose-Rich Polysaccharides in Treatment and Prevention of COVID-19 and Post-COVID-19 Syndrome.

M V Kiselevskiy, N Yu Anisimova, M I Bilan, A I Usov, N E Ustyuzhanina, A A Petkevich, I Zh Shubina, G E Morozevich, N E Nifantiev

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Russian journal of bioorganic chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

M V KiselevskiyBlokhin National Medical Research Center of Oncology, 115552 Moscow, Russia.
N Yu AnisimovaBlokhin National Medical Research Center of Oncology, 115552 Moscow, Russia.
M I BilanLaboratory of Glycoconjugate Chemistry, Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 119991 Moscow, Russia.
A I UsovLaboratory of Glycoconjugate Chemistry, Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 119991 Moscow, Russia.
N E UstyuzhaninaLaboratory of Glycoconjugate Chemistry, Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 119991 Moscow, Russia.
A A PetkevichBlokhin National Medical Research Center of Oncology, 115552 Moscow, Russia.
I Zh ShubinaBlokhin National Medical Research Center of Oncology, 115552 Moscow, Russia.
G E MorozevichOrekhovich Institute of Biomedical Chemistry, 119121 Moscow, Russia.
N E NifantievLaboratory of Glycoconjugate Chemistry, Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 119991 Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Symptoms of the new coronavirus infection that appeared in 2019 (COVID-19) range from low fever and fatigue to acute pneumonia and multiple organ failure. The clinical picture of COVID-19 is heterogeneous and involves most physiological systems; therefore, drugs with a wide spectrum of mechanism of action are required. The choice of the treatment strategy for post-COVID-19 syndrome is still a challenge to be resolved. Polysaccharides with a high fucose content derived from seaweed and marine animals can form the basis for the subsequent development of promising agents for the treatment of COVID-19 and post-COVID-19 syndrome. This class of biopolymers is characterized by a variety of biological activities, including antiviral, antithrombotic, anticoagulant, hemo-stimulating, anti-inflammatory and immune-regulatory. Low molecular weight derivatives of these polysaccharides, as well as synthetic oligosaccharides with a sufficient amount and sulfation type may be considered as the most promising compounds due to their better bioavailability, which undoubtedly increases their therapeutic potential.

Indexed as

COVID-19fucoidanfucosylated chondroitin sulfateheparan sulfateS-glycoprotein

Identifiers

PMID36325402
PMCPMC9584273

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.